Sermorelin dosage as the studies recorded it

Before the details

This page reports the sermorelin doses that appear in published studies. It is a record of what researchers administered, to which population, by which route — not a protocol to follow. There are no "take this much" instructions here, because the material this site concerns is research-grade peptide for laboratory study, not a medicine to self-administer. Where you see a figure like 30 mcg/kg/day, read it as "this is the dose the 1996 pediatric study used," not as guidance. The numbers exist to make the literature legible, and every one is cited.

Doses recorded in the research

Sermorelin doses in the literature span three distinct research settings:

• Pediatric GH-deficiency efficacy: 30 mcg/kg/day subcutaneously at bedtime in the multicenter trial that raised first-year height velocity from about 4.1 to 7-8 cm/year ^[1].
• Aging research in older men: 0.5 mg and 1 mg subcutaneously twice daily for 14 days, the protocol that reversed the age-related GH and IGF-1 decline at the high dose ^[2].
• Pharmacokinetic and diagnostic studies: intravenous doses of 0.25-2 mcg/kg, which elicited dose-dependent GH release in healthy men ^[3]; a single intravenous bolus (commonly around 1 mcg/kg) was historically used to test pituitary GH reserve.

These are study doses tied to specific populations and endpoints. They are reproduced here to document the literature, not to prescribe.

Routes studied

Three routes appear in the GHRH(1-29) record, with markedly different efficiency:

• Subcutaneous injection is the primary route in the efficacy studies ^[1][2].
• Intravenous administration was used in diagnostic and pharmacokinetic work, where it produced GH release within minutes ^[3].
• Intranasal delivery was tested historically but showed bioavailability of only about 3-5% ^[3] — the figure most often cited to explain why oral, sublingual, and troche "sermorelin" formulations are criticized as ineffective. Peptides are degraded in the gut and cross mucosa poorly.

The route shapes the result: the same molecule that drives a robust GH pulse subcutaneously is largely wasted across a mucosal surface.

Half-life and why timing appears in protocols

The native peptide is cleared from plasma in about 10-12 minutes, yet a single dose keeps serum GH elevated for roughly 3 hours ^[3]. That short half-life is why structure-modified analogs were developed — the D-Ala2 substitution lengthened half-life and reduced clearance in normal men ^[7], and the DAC technology behind longer-acting analogs extends the action further still.

Research protocols frequently dosed GHRH analogs before bedtime — the SMART trial used 1 mg/day before sleep ^[6] — to align with the body's natural nocturnal GH pulses, which concentrate during slow-wave sleep. This reflects study design, not a usage recommendation, and no human dosing instructions are provided here.

Stability and preparation notes

Lyophilized sermorelin acetate is reconstituted with a sterile diluent and, once reconstituted, is typically refrigerated. The peptide is supplied as a freeze-dried powder precisely because aqueous peptide solutions are prone to degradation ^[1]. Compounded preparations are made under USP <797> sterile-compounding standards. These notes describe how the substance is handled in research and compounding settings; they are not instructions for use.